Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study

Nintedanib is a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis (IPF). In a retrospective, real-world study across seven Greek hospitals, we evaluated the effectiveness and safety of nintedanib in routine clinical practice. Patients diagnosed with IPF, as per gu...

Descripción completa

Detalles Bibliográficos
Autores principales: Antoniou, Katerina, Markopoulou, Katerina, Tzouvelekis, Argyrios, Trachalaki, Athina, Vasarmidi, Eirini, Organtzis, Jiannis, Tzilas, Vasilios, Bouros, Evangelos, Kounti, Georgia, Rampiadou, Christina, Kotoulas, Serafeim-Chrysovalantis, Bardaka, Fotini, Bibaki, Eleni, Fouka, Evangelia, Meletis, Georgios, Tryfon, Stavros, Daniil, Zoe, Papakosta, Despina, Bouros, Demosthenes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6983495/
https://www.ncbi.nlm.nih.gov/pubmed/32010718
http://dx.doi.org/10.1183/23120541.00172-2019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6983495/
https://www.ncbi.nlm.nih.gov/pubmed/32010718
http://dx.doi.org/10.1183/23120541.00172-2019

Ejemplares similares